Since CD47 is overexpressed on cancer cells with respect to normal cells, we propose that the SIRPα domain of the licMAB would not bind to normal cells expressing CD47 but facilitate the targeting of dual antigen-expressing tumor cells led by high affinity binding to CD33. This evidence concerns the gene CD33 and neoplasm.